Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-26T01:15:40.310Z Has data issue: false hasContentIssue false
  • English
  • Français

American Leishmania spp: Formycin B treatment of cutaneous leishmaniasis in mice

Published online by Cambridge University Press:  06 April 2009

Tamara Rojas  and
J. L. Avila
Tamara Rojas
Affiliation:
Instituto de Biomedicina, Apartado 4043, Caracas 1010A, Venezuela
J. L. Avila*
Affiliation:
Instituto de Biomedicina, Apartado 4043, Caracas 1010A, Venezuela
*
*Reprint requests to this author.
Get access Rights & Permissions [Opens in a new window]

Extract

Using foot-pad infection of female C57BL/6, DBA/2J and NMRI-IVIC mice as an animal model for American cutaneous leishmaniasis (ACL), we evaluated the inhibitory effect of Formycin B (FoB) on the infection produced by 7 different Leishmania isolates. When treatment was initiated some days, or even some weeks, after infection a significant leishmanistatic effect was detected on mice infected with all Leishmania isolates, which reached 30–55 weeks for some isolates. The optimal dose schedule was 1·25 mg/kg body weight/day, injected intraperitoneally for 20 consecutive days. Significant differences in the sensitivity of various Leishmania spp. to FoB were found, either in vivo, or in vitro where a high [3H]FoB incorporation rate was found only for certain Leishmania isolates. The low toxicity of this drug and the sensitivity of the 7 Leishmania isolates tested suggest that FoB could be useful in the treatment of ACL.

Type
Research Article
Information
Parasitology , Volume 94 , Issue 3 , June 1987 , pp. 467 - 474
Copyright
Copyright © Cambridge University Press 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Avila, J. L., Biondo, F., Monzon, H. & Convit, J. (1982). Cutaneous leishmaniasis in mice: resistance to glucan immunotherapy, either alone or combined with chemotherapy. American Journal of Tropical Medicine and Hygiene 31, 53–9.Google Scholar
Avila, J. L. & Casanova, M. A. (1982). Comparative effects of 4-aminopyrazolopyrimidine, its 2′-deoxyriboside derivative, and allopurinol on in vitro growth of American Leishmania species. Antimicrobial Agents and Chemotherapy 22, 380–5.Google Scholar
Avila, J. L., Polegre, M. A., Avila, A. & Robins, R. K. (1986). Action of pyrazolopyrimidine derivatives on American Leishmania spp. promastigotes. Comparative Biochemistry and Physiology 83C, 285–9.Google ScholarPubMed
Berman, J. D. & Gallalee, J. V. (1985). Antileishmanial activity of human red blood cells containing Formycin A. Journal of Infectious Diseases 151, 698–703.Google Scholar
Berman, J. D., Keenan, C. M., Lamb, S. R., Hanson, W. L. & Waits, V. B. (1983). Leishmania donovani: Oral efficacy and toxicity of Formycin B in the infected hamster. Experimental Parasitology 56, 215–21.Google Scholar
Carson, D. A. & Chang, K.-P. (1981). Phosphorylation and antileishmanial activity of Formycin B. Biochemical and Biophysical Research Communications 100, 1377–83.Google Scholar
Coello, N. & Urbina, J. A. (1982). Isolation and purification of Leishmania brasiliensis amastigotes: its application to the comparative study of cell surface properties of amastigotes and promastigotes, NR stock. Acta Cientifica Venezolana 33, 144–51.Google Scholar
Cowan, M. J., Cashman, D. & Ammann, A. J. (1981). Effects of Formycin B on human lymphocyte deoxyribonucleic acid synthesis. Optimization of cell culture conditions. Biochemical Pharmacology 30, 2651–6.CrossRefGoogle ScholarPubMed
Ishizuka, M., Sawa, T., Hori, S., Takayama, H., Takeuchi, T. & Umezawa, H. (1968). Biological studies on Formycin and Formycin B. Journal of Antibiotics 21, 5–12.Google Scholar
Lainson, R. (1983). The American leishmaniases: some observations on their ecology and epidemiology. Transactions of the Royal Society of Tropical Medicine and Hygiene 77, 569–96.CrossRefGoogle ScholarPubMed
Osborne, W. R. E., Sullivan, J. L. & Scott, C. R. (1980). Formycin B, purine nucleoside phosphorylase and lymphocyte function. Immunological Communications 9, 257–67.Google Scholar
Perez, H., Labrador, F. & Torrealba, J. W. (1979). Variations in the response of five strains of mice to Leishmania mexicana. International Journal for Parasitology 9, 27–32.Google Scholar
Rainey, D. & Santi, D. V. (1983). Metabolism and mechanism of action of Formycin B in Leishmania. Proceedings of the National Academy of Sciences, USA 80, 288–92.CrossRefGoogle ScholarPubMed
Rainey, P. & Santi, D. V. (1984). Formycin B resistance in Leishmania. Biochemical Pharmacology 33, 1374–7.Google Scholar
Trotter, E. R., Peters, W. & Robinson, B. L. (1980). The experimental chemotherapy of leishmaniasis. VI. The development of rodent models for cutaneous infection with Leishmania major and L. mexicana amazonensis. Annals of Tropical Medicine and Parasitology 74, 299–319.Google Scholar
World Health Organization (1983). Document TDR/PR-6/83.7-Leish., pp. 193–205.Google Scholar